Ibogaine for MS, Parkinson’s, and TBI | Neuroregenerative Program

Neuroregenerative Program

WHAT TO EXPECT

Our Neuroregenerative Program was designed for people living with conditions like Parkinson’s, multiple sclerosis (MS), and essential tremors who wish to explore the use of ibogaine for these conditions.

Using optimized loading doses followed by extended microdosing, the protocol targets regeneration and an improved quality of life in the long term – backed by emerging data, ongoing research, and human-centric care.

This treatment uses an optimized ‘loading dose’ of ibogaine, ideal for people with physical challenges or age-related concerns, as a precursor to extended microdosing. You’ll be treated in accessible facilities and the comfort of a private room, with medical staff beside you throughout the treatment process. We also provide supportive physiotherapy to help you explore subtle changes in your body’s motility and mobility. This approach is designed to mitigate the complexities of the body’s needs and honor the complexity of chronic illness.

HOW DOES IT WORK?

Ibogaine treatment for neurodegenerative conditions is unproven and still experimental. However emerging research and clinical data suggest ibogaine can – to varying degrees – improve motor function, mood, and neuroplasticity, while enhancing cellular metabolism and reactivating underperforming areas of the brain.

In relation to Parkinson’s disease, ibogaine appears to stimulate the release of glial cell-derived neurotrophic factor (GDNF), a naturally occurring protein that helps repair and support dopamine-producing neurons. Early clinical trials have explored direct brain injection of GDNF as a treatment for Parkinson’s, and the increase of GDNF remains a target for Parkinson’s treatments. Although it has not yet entered clinical trials, ibogaine is one of the only known substances that can orally stimulate GDNF in deep brain regions.

In relation to multiple sclerosis, preclinical animal studies and Ambio’s own case study research suggest that ibogaine may help to repair myelin in the brain’s white matter. Some early preclinical work has shown similar remyelination in small animal models. This theory parallels clinical improvements in some MS patients, particularly those with early forms of the disease.

Who Can Benefit

Ambio’s Neuroregenerative Program was designed for people living with chronic neurological conditions who are looking for relief and renewed mobility. We’ve treated patients with Parkinson’s disease, multiple sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), traumatic brain injuries (TBI), essential tremors, chronic neuropathic pain, and more.

THIS PROGRAM MAY BENEFIT

People with mobility limitations or muscle spasticity
People who may not meet the screening criteria for higher-dose programs due to cardiac risk, age, or medication profiles
Those looking for a gentler, more medically adaptive approach to psychedelic medicine

If you’re navigating the physical, emotional, or spiritual weight of long-term illness, Ambio’s Neuroregenerative Program can provide a new option for managing symptoms and help you regain quality of life.

Mexico